CASI Pharmaceuticals (CASI) announced that its Board of Directors unanimously voted to appoint James Huang, a current independent board member, as Non-Executive Chairman of the Board. As part of this transition, Dr. Wei-Wu He will step down from the role as Executive Chairman and will remain a member of the Board of Directors. As Founder and Managing Partner of Panacea Venture, and previously Managing Partner at Kleiner Perkins China and Vivo Ventures, Huang has guided numerous cross-border companies through critical stages of growth, financing, and global expansion.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal
- CASI Pharmaceuticals Appeals Nasdaq Delisting Determination
- CASI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- CASI Pharmaceuticals Advances CID-103 in Promising ITP Study
- Casi Pharmaceuticals appoints James Hunag to board of directors